The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
S Nassereddine, CJ Lap, F Haroun, I Tabbara - Annals of hematology, 2017 - Springer
For decades, researchers have looked into the pathophysiology of acute myeloid leukemia
(AML). With the advances in molecular techniques, the two-hit hypothesis was replaced by a …
(AML). With the advances in molecular techniques, the two-hit hypothesis was replaced by a …
Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia
Acute myeloid leukemia (AML) is a lethal hematologic malignancy associated with poor
clinical outcomes. In recent years, mutations in the IDH1 and IDH2 genes have been …
clinical outcomes. In recent years, mutations in the IDH1 and IDH2 genes have been …
The role of IDH mutations in acute myeloid leukemia
G Montalban-Bravo, CD DiNardo - Future Oncology, 2018 - Taylor & Francis
Isocitrate dehydrogenases (IDHs) are enzymes involved in multiple metabolic and
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …
epigenetic cellular processes. Mutations in IDH1 or IDH2 are detected in approximately 20 …
AG-120, an oral, selective, first-in-class, potent inhibitor of mutant IDH1, reduces intracellular 2HG and induces cellular differentiation in TF-1 R132H cells and primary …
Point mutations in isocitrate dehydrogenase (IDH) define distinct subsets of acute
myelogenous leukemia (AML). IDH is a metabolic enzyme that interconverts isocitrate and α …
myelogenous leukemia (AML). IDH is a metabolic enzyme that interconverts isocitrate and α …
[HTML][HTML] AG-221, a small molecule mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in …
Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are observed in
patients with acute myeloid leukemia (AML). Leukemia-associated IDH1/2 mutations result …
patients with acute myeloid leukemia (AML). Leukemia-associated IDH1/2 mutations result …
[HTML][HTML] Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
GC Issa, CD DiNardo - Blood cancer journal, 2021 - nature.com
Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …
IDH mutations in acute myeloid leukemia
Acute myeloid leukemia is a heterogeneous group of diseases. Mutations of the isocitrate
dehydrogenase (IDH) genes represent a novel class of point mutations in acute myeloid …
dehydrogenase (IDH) genes represent a novel class of point mutations in acute myeloid …
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
I Abou Dalle, CD DiNardo - Therapeutic advances in …, 2018 - journals.sagepub.com
Recurrent mutations affecting cellular metabolism and epigenetic regulation are implicated
in the pathogenesis of acute myeloid leukemia (AML). Isocitrate dehydrogenase 2 (IDH2) …
in the pathogenesis of acute myeloid leukemia (AML). Isocitrate dehydrogenase 2 (IDH2) …
Targeting IDH mutations in AML: wielding the double-edged sword of differentiation
The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has
illuminated subclasses of the disease, with distinct driver mutations, that might be …
illuminated subclasses of the disease, with distinct driver mutations, that might be …
IDH2 inhibition in AML: finally progress?
EM Stein - Best practice & research Clinical haematology, 2015 - Elsevier
Isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to alpha ketoglutarate.
IDH occurs in three isoforms, IDH1, located in the cytoplasm, IDH2 located in the …
IDH occurs in three isoforms, IDH1, located in the cytoplasm, IDH2 located in the …